Abstract
At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Current Drug Targets
Title: PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Volume: 8 Issue: 9
Author(s): Douglas E. Vaughan, Bart M. De Taeye and Mesut Eren
Affiliation:
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Abstract: At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Export Options
About this article
Cite this article as:
Vaughan E. Douglas, De Taeye M. Bart and Eren Mesut, PAI-1 Antagonists: Predictable Indications and Unconventional Applications, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662364
DOI https://dx.doi.org/10.2174/138945007781662364 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thresholds for Central Blood Pressures and Augmentation Indices - are They Needed and How Far are We in the Process of Their Definition?
Current Hypertension Reviews Thrombophilia and Female Sex Hormones
Current Women`s Health Reviews Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Extending Arms of Insulin Resistance from Diabetes to Alzheimer’s Disease: Identification of Potential Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Markers of Early Vascular Ageing
Current Pharmaceutical Design The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin
Current Cardiology Reviews Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery Vitamin C: Basic Metabolism and Its Function as an Index of Oxidative Stress
Current Medicinal Chemistry Retinal Protein O-GlcNAcylation and the Ocular Renin-angiotensin System: Signaling Cross-roads in Diabetic Retinopathy
Current Diabetes Reviews Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design Proliferative Retinopathies: Animal Models and Therapeutic Opportunities
Current Neurovascular Research Editorial (Hot Topic :Incretins: Novel Cardiovascular Protection Agents)
Cardiovascular & Hematological Agents in Medicinal Chemistry Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Patient Centered Studies Focusing on Diabetes Self-Management: A Scoping Review
Current Diabetes Reviews Obesity Related Kidney Disease
Current Diabetes Reviews